This study highlights the promising potential of LC–MS as a powerful tool for mAb quality control within the context of upstream processing.

Findings demonstrate ATYR2810’s anti-tumor activity and increased survival in a model of glioblastoma multiforme (GBM), a primary form of brain cancer.